Business
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A hot, humid summer will slow coronavirus transmission but, on its own isn’t likely to end the COVID-19 pandemic, according to a new study.
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.
The study found that of the 15,000 patients who received either of the drugs were almost twice as likely to die compared to the patients who did not receive them. The research was published in the journal The Lancet.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
To learn more about ImmunityBio’s HIV drug candidate, BioSpace spoke to Dr. Whitney and Jeffrey Safrit, PhD, director of Cell-Mediated Therapies in Virology at NantKwest.
Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Henry Li, Sorrento’s co-founder, director, president and chief executive officer, did a follow-up interview with BioSpace to discuss the news and speculation surrounding it.
The hopes of billions of people are riding on at least one of the vaccine candidates for COVID-19 currently in clinical development becoming a commercialized preventative treatment for the world. While hopes are high, caution is still being urged by drugmakers and epidemiologists.
PNI will handle development of the vaccine and CanSinoBIO will take care of preclinical testing, human clinical trials, regulatory submissions and commercialization.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.